A bicarbonate-based purge solution for Impella® may be a viable alternative to heparin-based purge solution in patients who are heparin-intolerant and when heparin is contraindicated.
Claudius Mahr, DO, discusses outcome differences between patients with acute de novo cardiogenic shock and patients with chronic heart failure deteriorating to shock.
Adam Gottula, MD, discusses considerations for optimizing patient care when transporting patients supported with Impella or other mechanical circulatory support devices.
Chuck Simonton, MD, discusses the limitations of published papers that use administrative or payer databases as data sources and provides an AMI cardiogenic shock example.
Alexandra Lansky, MD, discusses a propensity-adjusted population-based analysis of Impella in patients undergoing high-risk PCI from a large-scale claims dataset.
Manreet Kanwar, MD, discusses the topic of heart recovery: How do we define it? How do we achieve it?
NPS-1674
This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].
The Protected PCI community
is now on HeartRecovery.com
Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.
